Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association
for the Study of Diabetes
*Simultaneous publication: This article is being simultaneously published in 2008 in Diabetes Care and Diabetologia by the American Diabetes Association and the European Association for the Study of Diabetes.
D.M.N. has received research grants from sanofi-aventis and support for educational programs from GlaxoSmithKline and Pfizer.
J.B.B. conducts research and/or serves on advisory boards under contract between the University of North Carolina and Amylin,
Bristol-Myers Squibb, GlaxoSmithKline, Hoffman-LaRoche, Eli Lilly, Novo Nordisk, Merck, Novartis, Pfizer, and sanofi-aventis.
M.B.D. has received research support from Eli Lilly, Merck, and Pfizer; serves on advisory boards to Amylin, GlaxoSmithKline,
Merck, and sanofi-aventis; and is on speakers bureaus for Amylin, Eli Lilly, GlaxoSmithKline, and Pfizer. E.F. has received
research support from AstraZeneca, Merck Sharp & Dohme, and Novartis and serves on scientific advisory boards for Amylin,
AstraZeneca, GlaxoSmithKline, Roche, Merck Sharp & Dohme, Novartis, Servier, sanofi-aventis, Boehringer Ingelheim, and Takeda.
R.R.H. has received grant support from Novartis, Bristol-Myers Squibb, Novo Nordisk, Pfizer, GlaxoSmithKline, and Merck and
serves on scientific advisory boards for Amylin, Novartis, Eli Lilly, Merck, and sanofi-aventis. R.S. serves on advisory boards
for Amylin, Bristol-Myers Squibb, Eli Lilly, Merck, and Takeda. B.Z. has received research support from Eli Lilly, GlaxoSmithKline,
Novartis, and Novo Nordisk and is a member of scientific advisory boards and/or has received honoraria for speaking from Amylin,
Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, sanofi-aventis, and Smiths Medical.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
